Humanwell Healthcare (600079.SH): HWH217 tablets approved for clinical trials in (WHO Group 1) pulmonary arterial hypertension.
Renfu Medicine (600079.SH) announcement, the company's wholly-owned subsidiary Hubei Bio-Pharmaceutical Industry Technology Research Institute Co.,Ltd.
Humanwell Healthcare (600079.SH) announced that its wholly-owned subsidiary Hubei Biomedical Industry Technology Research Institute Co., Ltd. recently received the "Clinical Trial Approval Notice" for HWH217 tablets issued by the National Medical Products Administration, permitting the company to conduct clinical trials for the treatment of arterial pulmonary hypertension in the WHO Group 1.
Related Articles
Shenwan Hongyuan Group (06806): Shenwan Hongyuan Group publicly issued short-term corporate bonds due in 2025 on November 4th, listed on the Shenzhen Stock Exchange.
CONSUN PHARMA (01681) spent 1.5009 million Hong Kong dollars to repurchase 100,000 shares on November 6th.
On November 6, EDIANYUN (02416) spent 264,000 Hong Kong dollars to repurchase 130,000 shares.
Shenwan Hongyuan Group (06806): Shenwan Hongyuan Group publicly issued short-term corporate bonds due in 2025 on November 4th, listed on the Shenzhen Stock Exchange.
CONSUN PHARMA (01681) spent 1.5009 million Hong Kong dollars to repurchase 100,000 shares on November 6th.
On November 6, EDIANYUN (02416) spent 264,000 Hong Kong dollars to repurchase 130,000 shares.
RECOMMEND
SERES Faces Market Test in Hong Kong: Shares Open Below Issue Price Despite HK$220 Billion Market Valuation
06/11/2025
Copper Prices Surge While Former “Copper King” Who Outpaced Huawei and Tencent Falls into Decline
06/11/2025
National Energy Administration Reports New-Type Energy Storage Capacity Exceeds 100 Million Kilowatts by End‑September
06/11/2025
